Introduction
The interaction between platelet glycoprotein Ibα (GpIbα) and von Willebrand factor (VWF) bound to damaged sub-endothelium represents the first step in platelet adhesion and is essential for normal hemostasis and vascular repair 1 . The interaction is mediated between the N-terminal ligand-binding domain of GpIbα and the VWF-A1 domain and is markedly enhanced as hydrodynamic shear increases, due to conformational activation of VWF or GpIbα or both 2, 3 . In pathological situations, such as stroke or myocardial infarction, vascular damage and enhanced shear rates occurring in stenotic arteries can cause inappropriate activation of GpIbα-VWF binding contributing to thrombus formation 4 . Data using monoclonal antibodies directed at
GpIbα has shown promise in targeting the GpIbα-VWF interaction as an antithrombotic therapy with the potential for reduced side effects of bleeding compared to currently available anticoagulants 5 . Blocking the GpIbα-VWF interaction is challenging for a small molecule due to the large 2600 Å 2 protein-protein interaction formed in the complex as defined by the GpIbα-VWF-A1 complex crystal structure 6 . The OS1 inhibitor is an 11meric peptide which was isolated from a cysteine-constrained phage display library and optimized such that it is capable of selectively disrupting the GpIbα-VWF interaction with a sub nanomolar potency 7 . To resolve how a small peptide can be such an effective inhibitor of a large protein-protein interaction we determined the GpIbα-OS1 peptide complex crystal structure.
Methods
Purified protein corresponding to a double deglycosylation mutant of GpIbα residues 1-265 (N21Q, N159Q) was prepared as previously described 8 Figure 1 ).
Results and discussion
The peptide binds to GpIbα at a site located between the extended regulatory (R) loop and the concave surface of the leucine rich repeats (LRRs numbered 1-8) ( Figure 1A ). The peptide adopts one and a half turns of an α -helix and its amphipathic nature presents a hydrophobic face (Ala6, Leu7 and disulphide) to contact the underside of the R-loop and side chains from LRRs 6,7 and a hydrophilic face presents charged side chains (Glu3, Arg4 and His8) to contact side chains from LRRs 3-7 ( Figure 1B ). Three subsites are involved in the interaction (S1-S3), S1 and S2 are contacts with the LRRs and S3 is contacts with the R-loop. S1 involves His8 forming a salt bridge with Glu128 and the aliphatic side chain of Arg4 extends over Tyr130, Val104 with the guanidinium group resting against Thr81 of LRR3. The S2 subsite involves a buried charge as the Glu3 side chain contacts Ser154 and is further buried by hydrophobic contacts with The GpIbα-OS1 structure suggests the difference in affinity is not due to a direct interaction with GpIbα but rather improved peptide stability.
A superposition of the GpIbα-OS1 structure with the GpIbα-VWF-A1 complex shows a steric overlap between the peptide and the VWF-A1 domain helix α 3 and the β3α2 loop ( Figure   2A ). OS1 is not a mimetic of the VWF-A1 interaction and the common contacts are limited to residues 236 and 237 in the R-loop with the peptide burying a total area of 500 Å 2 which is less than 20% of the surface area buried by VWF-A1 ( Figure 2B ). The R-loop in the GpIbα-VWF-A1 complex forms a highly ordered extended β -hairpin which is stabilized by the presence of an
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From 6 activating platelet type von Willebrand disease mutation of residue Met239 to Val which was used in determining the crystal structure 6 . The extended R-loop structure is critical to form main chain hydrogen bonds to the central β -sheet of VWF-A1 and residue Asp235 at the tip forms a salt bridge to Lys572 from the VWF-A1 β3α2 loop. In the wild type uncomplexed GpIbα the Rloop is poorly ordered with no electron density observed at the tip for residues 234-238 6, 8 . By contrast the GpIbα-OS1 structure has a highly ordered density for all residues in the R-loop and a folded back structure exists where Asp235 lies in a 3 10 helix which is pinned back by a direct helix capping interaction from the peptide Asn7 side chain ( Figure 2C ). This indicates the peptide has an allosteric component to its inhibition mode stabilizing a conformation of the Rloop which is incapable of forming key interactions with VWF-A1 (Supplementary Movie 2).
Platelets are major contributors to arterial thrombosis, and antiplatelet therapy has an established clinical benefit in the treatment and prevention of cardiovascular events. Antiplatelet agents such as integrin α IIb β 3 (glycoprotein IIb/IIIa) inhibitors, aspirin, and clopidogrel have proven efficacy but cardiovascular disease remains an important cause of mortality which has prompted the search for novel drugs against platelet-dependent thrombosis 13 . Ligand mimetic peptide complex crystal structures for the platelet receptors integrin α IIb β 3 with RGD 14 , and α 2 β 1 with a collagen peptide 15 have been described and the former are currently in therapeutic use for treatment of thromboembolic disorders. Our data provide a new scaffold for designing antiplatelet agents targeting the GpIbα-VWF-A1 interaction using small molecules or α-helical peptide derivatives of the OS1 sequence which are capable of occupying the GpIbα allosteric site defined in this complex structure. For personal use only. on September 13, 2017 . by guest www.bloodjournal.org From
